Oncology Conference Coverage Services: How DelveInsight Helps Pharma Teams Find Opportunities in a Fast-Moving Oncology Landscape

DelveInsight offers comprehensive oncology conference coverage services focused on high-impact conferences such as ASCO, ESMO, AACR, ASH, EHA, and many others, covering pre-conference planning, real-time on-site analysis, and post-conference strategic reporting, tailored to client-specific key intelligence topics (KITs) and therapeutic priorities.

LAS VEGAS, Sept. 30, 2026 /PRNewswire/ — Oncology moves faster than almost any other therapeutic area. New mechanisms, combination regimens, biomarker-defined subgroups, and cell and gene therapy platforms are reshaping standards of care year after year. Much of that change is first revealed at a handful of scientific meetings, not in journals or press releases.

Late-breaking abstracts, oral presentations, poster discussions, industry symposia and hallway conversations with KOLs shape how competitors position their assets and where clinical practice is heading. Teams that only skim the headlines miss the detail behind them: the subgroup analysis, the safety signal, the trial design shift, the questions clinicians ask from the floor.

That is why conference coverage has become a core competitive intelligence discipline for pharma and biotech. It is also why more companies now rely on specialist conference coverage services instead of stretching internal teams across parallel sessions in Chicago, Berlin, Orlando, and beyond.

Unlock the full potential of DelveInsight’s oncology conference coverage solutions @ https://www.delveinsight.com/consulting/conference-coverage-services

From Data Overload to Decisions: How DelveInsight’s Conference Coverage Works

A major oncology meeting can include thousands of abstracts. The challenge is not access to information but deciding what matters, capturing it accurately, and turning it into something your leadership can act on. DelveInsight’s competitive intelligence conference coverage for pharma follows three connected stages.

1. Pre-Congress: Plan Around Your Priorities

Coverage starts before the meeting opens. DelveInsight’s team works with you to define your Key Intelligence Topics (KITs) and Key Intelligence Questions (KIQs), then builds a conference planner around them.

• A daily planner mapped to your areas of interest
• Prioritization and selection of abstracts from the full program
• Categorization by format (poster, oral, symposium, session) and by priority
• Review of KIQs and key data points with your team before anyone steps on the floor

Your analysts are not covering everything. They are covering what matters to your portfolio, pipeline, and market position.

2. During the Congress: Capture Intelligence in Real Time

Subject matter experts attend sessions and gather intelligence against the plan.

• Coverage of oral presentations, plenary discussions, late-breaking sessions, corporate symposia, and poster sessions
• Photographs of slides and posters to preserve exact data points
• Interviews with KOLs, presenters, oncologists and other stakeholders to gauge how audiences react to new data
• Collection of conference materials that reveal competitor product positioning and key messaging
• Social media tracking for instant read-outs on priority targets

DelveInsight also provides daily updates, so your team learns what happened while decisions can still be influenced.

3. Post-Congress: Turn Insights Into Strategy

After the meeting, the information is organized into a structured repository and analyzed against your KIQs. Deliverables can include an executive summary, a detailed report, and briefing presentations, in the format your stakeholders prefer. They highlight recent breakthroughs, near-term plans, and upcoming milestones.

Ready to turn your next oncology conference into a strategic advantage? Schedule a free consultation

The Conferences That Matter Most in Oncology

Oncology data reaches the market in waves, and each major meeting brings its own kind of intelligence. Some deliver practice-changing Phase III results. Others reveal early science that will define the pipeline three years from now. Knowing what each conference is best for, and having a partner to capture it, lets you plan coverage instead of reacting to headlines. DelveInsight’s oncology conference coverage spans major oncology events, including ASCO, ESMO, AACR, ASH, EHA, SITC, ASTRO, SOHO, IASLC, ESMO-IO, the European CAR T-cell Meeting, and others.

ASCO Oncology Conference

The ASCO Annual Meeting is the premier global event for oncology professionals to network, collaborate, and shape the future of cancer care. It is where pivotal Phase III readouts, late-breaking abstracts, and updated survival data are presented to the clinicians who will prescribe the resulting therapies. One ASCO plenary can change treatment guidelines, competitor valuations, and your own launch strategy within days. The scale is the challenge. The program spans hundreds of sessions across dozens of tumor types, and most teams cannot cover it all without missing something that matters.

What DelveInsight can offer you from the ASCO Oncology Conference?

• Your Key Intelligence Topics and Key Intelligence Questions (KIQs) drive a daily planner, so analysts cover the abstracts that affect your portfolio rather than everything.
• Detailed breakdowns of efficacy, safety, subgroup, and study design data, including first-in-class therapies and new mutation targets.
• Analysis of corporate symposia, booth messaging, and presentation framing to show how rivals are positioning their assets.
• Interviews and floor conversations that show whether new data is being read as practice-changing or incremental.
• Evidence on how new results might alter standards of care, sequencing, and patient segmentation.
• Fast summaries during the meeting, followed by an executive summary and detailed report aligned to your KIQs.

Get a sneak peek of DelveInsight’s analysis of key themes and results presented at ASCO 2026 @ ASCO 2026 Conference Coverage

AACR Oncology Conference

The AACR Annual Meeting is the place where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest breakthroughs. Compared with ASCO, AACR leans toward translational and preclinical science, novel targets, mechanisms of resistance, early-phase data, and emerging modalities. That makes it one of the best places to spot competitors and technologies before they show up in pivotal trials. If ASCO tells you what is changing practice today, AACR tells you what is coming next.

What DelveInsight can offer you from the AACR Oncology Conference?

• Identification of novel targets, first-in-human data, and preclinical programs that may become future competitors or partnering candidates.
• Coverage of developments in areas such as immunotherapy, cell and gene therapy, ADCs, radiopharmaceuticals, oncolytic viruses, and novel delivery systems.
• Analysis of biomarker-driven approaches and resistance mechanisms that could reshape patient selection in your indication.
• Mapping of who is working on what, so you can see where the field is crowded and where it is not.
• Insights drawn from interactions with presenters and researchers during poster sessions.
• Daily highlights and post-meeting reports that translate scientific findings into strategic implications for R&D and business development.

DelveInsight also offers dedicated AACR Annual Meeting event coverage, tailored to your areas of interest. Visit DelveInsight’s AACR Conference Coverage

ESMO Congress

The ESMO Congress is a leading international oncology forum that brings together clinicians, researchers, patient advocates, journalists and healthcare industry professionals from around the globe. It carries strong weight in Europe, where data can influence EMA thinking, HTA discussions, and regional treatment guidelines. Many companies also use ESMO as the main autumn stage for data that follows ASCO updates. ESMO 2026 will take place from October 23–27. The ESMO family also includes focused meetings such as ESMO-IO and ESMO Asia, which add depth in immuno-oncology and regional practice.

What DelveInsight can offer you from the ESMO Conference?

• A conference playbook and abstract prioritization built around your assets, competitors, and indications, ready before the meeting begins.
• Analysis of Key Oral Abstracts and other formats, including Mini Orals, Industry Satellite Symposia, Proffered Paper Sessions and Educational Sessions.
• Assessment of new data and how it may shift treatment strategy across tumor types.
• Insight into how clinicians, payers, and regulators are likely to interpret new data, which supports launch sequencing and evidence planning.
• Perspectives from investigators and oncologists that answer your KIQs.
• Observation of collaborations and partnership announcements happening around the congress.
• A detailed final report and briefing presentation ready for leadership.

Connect with us now to discuss your ESMO 2026 conference coverage priorities and get a tailored proposal 

ASH Annual Meeting

The ASH Annual Meeting & Exposition is the world’s premier event in hematology, covering leukemia, lymphoma, myeloma, and other blood disorders. For companies developing CAR-T therapies, bispecific antibodies, targeted agents or cell and gene therapies in hematologic malignancies, ASH is the year’s defining data event. Many of the field’s most closely watched updates, such as durability of response, MRD data, real-world outcomes, and safety signals in new modalities, appear here first. It also falls near the end of the calendar, so it sets the competitive backdrop for the coming year’s planning cycle.

What DelveInsight can offer you from the ASH Conference?

• Coverage of clinical updates across leukemia, lymphoma, myeloma, and related indications, with attention to class-level trends and potential class failures.
• Analysis of efficacy, durability and safety data for CAR-T and other advanced modalities, building on DelveInsight’s experience covering CAR-TCR summits for novel CAR-T therapies in B-cell malignancies.
• Side-by-side views of how rival programs compare on response, tolerability, and trial design.
• A ranked coverage list so analysts can focus on the oral and poster presentations that speak to your KIQs.
• Feedback from hematologists and investigators on how new data will shape treatment sequencing.
• Daily updates plus a consolidated report to inform year-end portfolio reviews and next-year planning.

EHA Congress

The European Hematology Association (EHA) Congress is one of the world’s major hematology meetings. It reports on malignant and non-malignant blood disorders, including leukemia, lymphoma, myeloma and related conditions. EHA falls in the first half of the year, about six months before ASH, so it is often where companies show follow-up data, early signals from new modalities, and European clinical perspectives before the year-end ASH cycle. For teams in hematologic oncology, EHA answers a strategic question: what has changed since last December, and what is likely to be presented at ASH?

What DelveInsight can offer you from the EHA Conference?

• Coverage of new and updated clinical data across leukemia, lymphoma, myeloma, and related indications, with attention to class-level trends and potential class failures.
• Analysis of CAR-T, bispecific antibody, targeted therapy, and cell and gene therapy data, building on DelveInsight’s experience covering CAR-TCR summits for novel CAR-T therapies in B-cell malignancies.
• Comparisons of rival programs on response depth, durability, tolerability, and trial design.
• Read-throughs on which programs are advancing and what may follow at ASH, to help you plan ahead.
• Feedback from hematologists and investigators on how new data is likely to shape treatment sequencing and adoption.
• A ranked list of oral and poster presentations mapped to your Key Intelligence Questions (KIQs), so analysts focus on what affects your assets.
• Daily updates during the congress, followed by an executive summary and detailed report.

Catch up on the latest findings from the EHA 2026 @ DelveInsight’s EHA 2026 Conference Analysis

SITC Annual Meeting

The Society for Immunotherapy of Cancer (SITC) Annual Meeting is dedicated to cancer immunotherapy, from checkpoint inhibitors and combinations to cell therapies, cancer vaccines, TIL therapies, T-cell engagers, and next-generation immune-modulating approaches. SITC 2026 will take place from November 4–8.

For anyone working in immuno-oncology, SITC shows where the science is heading, which mechanisms are gaining traction and which are struggling. That includes the ‘hot’ versus ‘cold’ tumor question, since work on turning immune-cold tumors into responsive ones is a central theme of the field.

What DelveInsight can offer you from the SITC Conference?

• Coverage of new data across checkpoint inhibitors, combination regimens, cell therapies, vaccines, and emerging immune-modulating approaches.
• Analysis of shifts in treatment patterns and strategies for tumors that have historically responded poorly to immunotherapy.
• Tracking of biomarker-driven patient selection, resistance mechanisms, and translational findings that could change trial design in your indication.
• Early identification of mechanisms that are gaining momentum and those showing signs of potential class failure.
• Observation of on-site company activity and collaborations that may point to licensing or partnership targets.
• Interviews that capture how the immunotherapy community is interpreting new data and where it sees the next opportunities.
• Post-event reporting timed to feed portfolio reviews and next-year strategy, with an executive summary and detailed report tied to your KIQs.

Reach out today to discuss your SITC 2026 priorities and receive a customized coverage proposal

Why Pharma Teams Choose DelveInsight for Corporate Conference Coverage?

As a leader, you’re aware that conferences are crucial gatherings where company updates, industry conversations, and interactions with key opinion leaders come together, offering you essential firsthand and secondary competitive insights.

• Are you leveraging these conferences to gather vital competitive insights and maintain a leading edge?
• Would you like to gain an in-depth understanding of major developments, pipeline progress, and shifting views on key therapeutic strategies? 
• Are you interested in learning what your competitors, key opinion leaders, and industry decision-makers are thinking to strategically inform your market approach?

By partnering with DelveInsight, you can take advantage of these conferences to stay informed about cutting-edge industry trends, emerging technologies, and market dynamics, enhancing your strategic decision-making. We specialize in thorough pre-conference planning, real-time intelligence gathering during the event, and comprehensive post-conference insights.

Ready to unlock the potential of your next conference? Schedule a call with our expert today!

Pharma Competitive Intelligence Service tailored to the Oncology Domain: The oncology domain is one of our fortes, providing detailed insights into advancements across oncology such as multiple myeloma, NSCLC, CTCL, PTCL, Ewing sarcoma, PCPG, etc. to name a few. Our services analyze competitors’ pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to oncology. The AI-powered intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area.

Rare Disease Consulting Services: In the rare disease domain, one of our core areas of expertise, we provide strategic intelligence that enables clients to navigate the complexities of specialized markets. Our analysts closely track worldwide R&D advancements, competitive activity, and evolving regulatory dynamics to deliver customized insights that support product positioning and investment decisions. Through comprehensive conference assessments and detailed competitive benchmarking, we help clients minimize risk, optimize portfolios, and accelerate the journey of therapies from development through commercialization.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP